Infammation and glucose sensors: Use of dexamethasone to extend glucose sensor function and life span in vivo

Journal of Diabetes Science and Technology

Volumn 1, Issue 4, 2007, Pages 496-504

  Klueh, Ulrike ^a   Kaur, Manjot ^a   Montrose, David C ^a   Kreutzer, Donald L ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Anti infammatory therapy; Dexamethasone; Diabetes; Fbrosis; Implantable glucose sensor; Infammation; Murine (mouse); Sensor function in vivo; Tissue responses; Vessel regression

Indexed keywords

EID: 79951481792     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680700100407     Document Type: Article

References (16)

1. Djakoure-Platonoff C, Radermercker R, Reach G, Slama G, Selam JI. Accuracy of the continuous glucose monitoring system in inpatient and outpatient conditions. Diabetes Metab. 2003 Apr; 29(2 Pt 1):159-62.
2. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan; 29(1):44-50.
3. Tansey MJ, Beck RW, Buckingham BA, Mauras N, Fiallo-Scharer R, Xing D, Killman C, Tamborlane WV, Ruedy KJ; The Diabetes Research in Children Network (DirecNet) Study Group. Accuracy of the modifed Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. Diabetes Technol Ther. 2005 Feb; 7(1):109-14.
4. Friedl KE. Corticosteroid modulation of tissue responses to implanted sensors. Diabetes Technol Ther. 2004 Dec; 6(6):898-901.
5. Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the infammatory tissue response to implantable medical devices. J Biomed Mater Res. 2002 Aug; 61(2):180-7.
6. Pavanetto F, Genta I, Giunchedi P, Conti B, Conte U. Spraydried albumin microspheres for the intra-articular delivery of dexamethasone. J Microencapsul. 1994 Jul-Aug; 11(4):445-54.
7. Sanders LM, Kell BA, McRae GI, Whitehead GW. Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer. J Pharm Sci. 1986 Apr; 75(4):356-60.
8. Friedl KE. Analysis: overcoming the "valley of death": mouse models to accelerate translational research. Diabetes Technol Ther. 2006 Jun; 8(3):413-4.
9. Friedl KE. Analysis: mouse models of glucose sensor biocompatibility. Diabetes Technol Ther. 2005;7(5):738-40.
10. Klueh U, Kreutzer DL. Murine model of implantable glucose sensors: a novel model for glucose sensor development. Diabetes Technol Ther. 2005 Oct; 7(5):727-37.
11. Klueh U, Liu Z, Cho B, Ouyang T, Feldman B, Henning TP, Kaur M, Kreutzer D. Continuous glucose monitoring in normal mice and mice with prediabetes and diabetes. Diabetes Technol Ther. 2006 Jun; 8(3):402-12.
12. Klueh U, Dorsky DI, Kreutzer DL. Enhancement of implantable glucose sensor function in vivo using gene transfer-induced neovascularization. Biomaterials. 2005 Apr; 26(10):1155-63.
13. Velho G, Froguel P, Thevenot DR, Reach G. Strategies for calibrating a subcutaneous glucose sensor. Biomed Biochim Acta. 1989;48(11-12):957-64.
14. Mercado RC, Moussy F. In vitro and in vivo mineralization of Nafon membrane used for implantable glucose sensors. Biosens Bioelectron. 1998 Feb; 13(2):133-45.
15. Ward WK, Troupe JE. Assessment of chronically implanted subcutaneous glucose sensors in dogs: the effect of surrounding fuid masses. Asaio J. 1999 Nov-Dec; 45(6):555-61.
16. Schramm R, Thorlacius H. Staphylococcal enterotoxin B-induced acute infammation is inhibited by dexamethasone: important role of CXC chemokines KC and macrophage infammatory protein 2. Infect Immun. 2003 May; 71(5):2542-7.